2024 Tharimmune - 17-Nov-2023 ... Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and ...

 
Nov 28, 2023 · Tharimmune, Inc. THAR shares dropped 73% to $0.9489. Tharimmune priced its $10 million public offering 10 million common shares at $1 per share. . Tharimmune

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The …Nov 27, 2023 · Tharimmune shares opened at $2.93, later reaching a high of $4.79. The stock recently sold for $4.20, up 46%, at around 10:10 a.m. ET. Earlier Monday, Tharimmune said that a Phase 1 study for ... About Tharimmune, Inc. Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and …THAR / Tharimmune Inc short borrow fee rates are shown in the following table. This table shows the interest rate that must be paid by a short seller of US:THAR to the lender of that security. This fee is shown as an annual percentage rate (APR). Lenders are funds or individuals that own the security that have indicated to the broker that they ...About Tharimmune, Inc. Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases.Nov 28, 2023 · Tharimmune has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 shares of common stock and/or Pre-Funded Warrants to cover over-allotments at the public offering ... Tharimmune, Inc. THAR announced data from an early-stage study on TH104 and the development timeline for a phase IIa study in chronic pruritis in primary biliary cholangitis (“PBC”) patients.Tharimmune Inc. is a biotechnology company. It involved in developing a portfolio of therapeutic candidates for rare immune, inflammatory and oncologic diseases. Tharimmune Inc., formerly known as ...Nov 28, 2023 · Tharimmune, Inc. THAR announced data from an early-stage study on TH104 and the development timeline for a phase IIa study in chronic pruritis in primary biliary cholangitis (“PBC”) patients. Tharimmune, Inc. THAR announced data from an early-stage study on TH104 and the development timeline for a phase IIa study in chronic pruritis in primary biliary cholangitis (“PBC”) patients.Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and orphan ...Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year On November 17, 2023, Tharimmune, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to its Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware pursuant to which it effected a 1-for-25 …Tharimmune, Inc. Common Stock (THAR) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Tharimmune Inc (NASDAQ: THAR) shares are trading lower by 71% to $1.00 Tuesday morning after the company priced an underwritten public offering of 10 million shares of common stock or pre-funded ...Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in primary biliary cholangitis (PBC), …U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Tuesday. The Dow traded up 0.27% to 35,429.20 while the NASDAQ rose 0.12% to 14,258.32 ...Nov 27, 2023 · Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and orphan ... Tharimmune Inc THAR has executed an exclusive worldwide licensing agreement with Avior Inc. to develop, market, and commercialize a clinical-stage asset, AV104 (to be renamed TH104). TH104 has a ...About Tharimmune, Inc. Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases.Nov 30, 2023 · View THAR: Tharimmune, Inc.investment & stock information. Get the latest THAR: Tharimmune, Inc. detailed stock quotes, stock data, Real-Time ECN, charts, stats and ... 22-Sept-2023 ... ... Tharimmune, Inc., ("Tharimmune"). The corporate name change is based on the Greek word "thárros", translated to mean courage and reflects ...Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and orphan ...Tharimmune Inc (NASDAQ: THAR) shares are trading lower by 71% to $1.00 Tuesday morning after the company priced an underwritten public offering of 10 million shares of common stock or pre-funded ...Nov 28, 2023 · Tharimmune Inc (NASDAQ: THAR) shares are trading lower by 71% to $1.00 Tuesday morning after the company priced an underwritten public offering of 10 million shares of common stock or pre-funded ... Tharimmune Inc (NASDAQ: THAR) shares are trading lower by 71% to $1.00 Tuesday morning after the company priced an underwritten public offering of 10 million shares of common stock or pre-funded ...Nov 28, 2023 · Tharimmune Inc (NASDAQ: THAR) shares are trading lower by 71% to $1.00 Tuesday morning after the company priced an underwritten public offering of 10 million shares of common stock or pre-funded ... Sep 22, 2023 · About Tharimmune, Inc. Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The stock price for Tharimmune ( NASDAQ: THAR) is $ 3.04 last updated November 24, 2023, 11:14 AM PST. Q.Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ...Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company’s pre-clinical immuno ...Nov 20, 202308:54 PST. T THAR. Tharimmune Inc T THAR shares are trading lower by 9.7% to $0.19 during Monday's session, pulling back following Friday's strength, after the company announced it is undergoing a 1-for-25 reverse stock split of its shares. This decision, approved by stockholders in October, will take effect on November 20.Get the latest Tharimmune, Inc. (THAR) stock news and headlines to help you in your trading and investing decisions.Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ...Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ...Tharimmune, Inc.THAR announced data from an early-stage study on TH104 and the development timeline for a phase IIa study in chronic pruritis in primary biliary cholangitis (“PBC”) patients.Tharimmune, Inc.’s Post Tharimmune, Inc. 261 followers 1y Report this post Hillstream BioPharma is pleased to share our attendance at the 12th Annual World Orphan Drug Congress USA on July 11 ...Tharimmune priced its $10 million public offering 10 million common shares at $1 per share. Shares of SenesTech, Inc. (NASDAQ: SNES) were down 50% to $0.9181 after the company reported pricing of ...Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ...6 days ago ... Tharimmune (NASDAQ: THAR) is one of those little poster boy stocks to see how the funding of development pharma companies [email protected]. 1200 Route 22 East Suite 2000 Bridgewater, NJ 08807 Tel: 1-908-955-3140 eMail: [email protected]. Latest News. Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc. September 22, 2023; Dawson James Securities Announces ...17-Nov-2023 ... Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and ...About Tharimmune, Inc. Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases.Nov 28, 2023 · Tharimmune, Inc. THAR announced data from an early-stage study on TH104 and the development timeline for a phase IIa study in chronic pruritis in primary biliary cholangitis (“PBC”) patients. That public offering has Tharimmune selling 10 million shares of THAR stock. These shares are being sold for $1 each. Underwriters also have a 45-day option to acquire another 1.5 million shares ...Tharimmune, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for ...Tharimmune Inc THAR has executed an exclusive worldwide licensing agreement with Avior Inc. to develop, market, and commercialize a clinical-stage asset, AV104 (to be renamed TH104). TH104 has a ...Nov 18, 2023 · Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ... See the latest Altimmune Inc stock price (ALT:XNAS), related news, valuation, dividends and more to help you make your investing decisions.7 days ago ... THAR Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis ...Nov 28, 2023 · Tharimmune (NASDAQ: THAR) is one of those little poster boy stocks to see how the funding of development pharma companies works. They had a bit of good news yesterday, passed one of the valuation stages in a development process. So, the stock rose 46% - which is about right. Pass a valuation stage and value increases. Tharimmune, Inc. Common Stock (THAR) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or “uncontrollable itching” in PBC, a rare and orphan ... Tharimmune (NASDAQ:THAR) announced the pricing of an underwritten public offering of 10,000,000 shares of common stock. Each share of common stock is being sold at a public offering price of $1.00 ...Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or “uncontrollable itching” in PBC, a rare and orphan ... Tharimmune, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism …Kjøp Tharimmune (THAR) aksjen. Hos Nordnet kan du handle fra 1 kr i kurtasje. Klikk her for å følge aksjekursen i realtid.Kjøp Tharimmune (THAR) aksjen. Hos Nordnet kan du handle fra 1 kr i kurtasje. Klikk her for å følge aksjekursen i realtid.Tharimmune (NASDAQ: THAR) is one of those little poster boy stocks to see how the funding of development pharma companies works. They had a bit of good news yesterday, passed one of the valuation stages in a development process. So, the stock rose 46% - which is about right. Pass a valuation stage and value increases.Kjøp Tharimmune (THAR) aksjen. Hos Nordnet kan du handle fra 1 kr i kurtasje. Klikk her for å følge aksjekursen i realtid.Tharimmune () stock is rising higher alongside a new licensing agreement. The company is going to handle the development of TH104. This news brings heavy trading to THAR stock on Tuesday.TeraImmune, Inc. is a biotechnology company that develops innovative immune-cell therapies. Our investigational technology programs regulatory T (Treg) cells to recognize …Nov 28, 2023 · Tharimmune, Inc. THAR shares dropped 73% to $0.9489. Tharimmune priced its $10 million public offering 10 million common shares at $1 per share. Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and …Nov 27, 2023 · Tharimmune shares opened at $2.93, later reaching a high of $4.79. The stock recently sold for $4.20, up 46%, at around 10:10 a.m. ET. Nov 28, 2023 · BRIDGEWATER, NJ / ACCESSWIRE / November 27, 2023Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic... Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company’s pre-clinical immuno ...THAR - Tharimmune, Inc. NasdaqCM - NasdaqCM Real Time Price. Currency in USD. 0.9510. -2.5590 (-72.91%) As of 03:05PM EST. Market open. Stock chart is not supported by your current browser. Gain ...Tharimmune Inc. stock performance at a glance Check Tharimmune Inc.’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. THAR Stock PerformanceItem 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year On November 17, 2023, Tharimmune, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to its Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware pursuant to which it effected a 1-for-25 …Tharimmune Inc. is a biotechnology company. It involved in developing a portfolio of therapeutic candidates for rare immune, inflammatory and oncologic diseases. Tharimmune Inc., formerly known as ...Tharimmune Inc (THAR) has seen a -23.43% fall in stock performance for the week, with a -10.37% decline in the past month and a -36.59% plunge in the past quarter. The volatility ratio for the week is 19.62%, and the volatility levels for the past 30 days are at 16.50% for THAR. The simple moving average for the past 20 days is -6.70% …Tharimmune, Inc. THAR announced data from an early-stage study on TH104 and the development timeline for a phase IIa study in chronic pruritis in primary biliary cholangitis (“PBC”) patients.That public offering has Tharimmune selling 10 million shares of THAR stock. These shares are being sold for $1 each. Underwriters also have a 45-day option to acquire another 1.5 million shares ...Nov 30, 2023 · View THAR: Tharimmune, Inc.investment & stock information. Get the latest THAR: Tharimmune, Inc. detailed stock quotes, stock data, Real-Time ECN, charts, stats and ... Nov 28, 2023 · Tharimmune (NASDAQ:THAR) announced the pricing of an underwritten public offering of 10,000,000 shares of common stock. Each share of common stock is being sold at a public offering price of $1.00 ... Nov 28, 2023 · That public offering has Tharimmune selling 10 million shares of THAR stock. These shares are being sold for $1 each. Underwriters also have a 45-day option to acquire another 1.5 million shares ... Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in primary biliary cholangitis (PBC), a rare orphan ...vs. Previous Quarter. View THAR: Tharimmune, Inc.investment & stock information. Get the latest THAR: Tharimmune, Inc. detailed stock quotes, stock data, …Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or “uncontrollable itching” in PBC, a rare and orphan ... Tharimmune

Tharimmune, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for drug resistant and devastating cancers. It also develops the Trident Artificial Intelligence (TAI) precision medicine platform which is used to identify .... Tharimmune

tharimmune

Nov 28, 2023 · That public offering has Tharimmune selling 10 million shares of THAR stock. These shares are being sold for $1 each. Underwriters also have a 45-day option to acquire another 1.5 million shares ... Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The …Nov 28, 2023 · Tharimmune Inc THAR shares are trading lower by 71% to $1.00 Tuesday morning after the company priced an underwritten public offering of 10 million shares of common stock or pre-funded warrants at ... Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ...About Tharimmune, Inc. Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases.Research Tharimmune's (Nasdaq:THAR) stock key valuation metrics while comparing it with its industry peers & market side by side. Dashboard Markets Discover Watchlist Portfolios Screener Tharimmune, Inc.hyperimmune: [ hi″per-im-mūn´ ] possessing very large quantities of specific antibodies in the serum.Tharimmune Inc THAR released phase 1 data with TH104, a proprietary transmucosal buccal film.. The first Phase 1 trial was a crossover study of TH104 transmucosal buccal film compared to a tablet ...Nov 20, 2023 · Tharimmune says the main purpose of its reverse stock split is increasing the price of THAT shares. The company is doing this to get its shares above the $1 minimum bid price needed to remain on ... Nov 28, 2023 · Tharimmune priced its $10 million public offering 10 million common shares at $1 per share. Shares of SenesTech, Inc. (NASDAQ: SNES) were down 50% to $0.9181 after the company reported pricing of ... Tharimmune Inc. is a biotechnology company. It involved in developing a portfolio of therapeutic candidates for rare immune, inflammatory and oncologic diseases. Tharimmune Inc., formerly known as ...13-Jun-2022 ... Each share is being sold to the public at a price of $0.50 for gross proceeds of $2,650,000, before deducting underwriting discounts and ...Nov 28, 2023 · Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and orphan ... Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and orphan ...Tharimmune Announces 1-for-25 Reverse Stock Split. BRIDGEWATER, NJ / ACCESSWIRE / November 17, 2023 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology ...Nov 27, 2023 · Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ... 7 days ago ... Tharimmune also announced plans on a development timeline for a Phase 2a study in chronic pruritis in primary biliary cholangitis (PBC) patients ...Nov 18, 2023 · Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ... Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and orphan ...Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or “uncontrollable itching” in PBC, a rare and orphan ...Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or 'uncontrollable itching' in primary biliary cholangitis (PBC), …Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and orphan ...Tharimmune Inc (NASDAQ: THAR) shares are trading lower by 9.7% to $0.19 during Monday's session, pulling back following Friday's strength, after the company announced it is undergoing a 1-for-25 ...Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and …Nov 28, 2023 · Tharimmune, Inc. (THAR Quick Quote THAR - Free Report) announced data from an early-stage study on TH104 and the development timeline for a phase IIa study in chronic pruritis in primary biliary ... U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Tuesday. The Dow traded up 0.27% to 35,429.20 while the NASDAQ rose 0.12% to 14,258.32 ...Tharimmune, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for ...Chg %. $2.8750. -0.1450. -4.80%. Tharimmune Inc. advanced stock charts by MarketWatch. View THAR historial stock data and compare to other stocks and exchanges.Nov 17, 2023 · Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and orphan ... Nov 27, 2023 · Tharimmune shares opened at $2.93, later reaching a high of $4.79. The stock recently sold for $4.20, up 46%, at around 10:10 a.m. ET. Earlier Monday, Tharimmune said that a Phase 1 study for ... Nov 28, 2023 · Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company’s pre-clinical immuno ... TeraImmune, Inc. is a biotechnology company that develops innovative immune-cell therapies. Our investigational technology programs regulatory T (Treg) cells to recognize …Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and orphan ...A high-level overview of Tharimmune, Inc. (THAR) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Nov 27, 2023 · Tharimmune shares opened at $2.93, later reaching a high of $4.79. The stock recently sold for $4.20, up 46%, at around 10:10 a.m. ET. Earlier Monday, Tharimmune said that a Phase 1 study for ... About Tharimmune Inc ... Tharimmune, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer ...Tharimmune () stock is rising higher alongside a new licensing agreement. The company is going to handle the development of TH104. This news brings heavy trading to THAR stock on Tuesday.Latest News. Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis November 6, 2023; Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc. September 22, 2023 Dawson James Securities …Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ...About Tharimmune, Inc. Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases.Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a ...Nov 28, 2023 · Tharimmune priced its $10 million public offering 10 million common shares at $1 per share. Shares of SenesTech, Inc. (NASDAQ:SNES) were down 50% to $0.9181 after the company reported pricing of ... That public offering has Tharimmune selling 10 million shares of THAR stock. These shares are being sold for $1 each. Underwriters also have a 45-day option to acquire another 1.5 million shares ...Tharimmune, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for ...Tharimmune closes $11M in public offering: The company, which is developing therapies that aim to treat rare, inflammatory, and oncologic conditions, announced Thursday that it sold 11 million ...Tharimmune, Inc. (THAR) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 3.4311 +0.5511 (+19.14%) As of 03:38PM EST. Market open. Time Period: Nov …That public offering has Tharimmune selling 10 million shares of THAR stock. These shares are being sold for $1 each. Underwriters also have a 45-day option to acquire another 1.5 million shares ...Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ...Tharimmune is a hot topic on Tuesday after the company underwent a name change and also changed to the THAR stock ticker. Tharimmune is a hot topic on Tuesday after the company underwent a name ...Tharimmune is a hot topic on Tuesday after the company underwent a name change and also changed to the THAR stock ticker. Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ...Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and …Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and orphan ...Company profile for Tharimmune Inc. (THAR) with a description, list of executives, contact details and other key facts.Tharimmune shares opened at $2.93, later reaching a high of $4.79. The stock recently sold for $4.20, up 46%, at around 10:10 a.m. ET. Earlier Monday, Tharimmune said that a Phase 1 study for ...Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The …That public offering has Tharimmune selling 10 million shares of THAR stock. These shares are being sold for $1 each. Underwriters also have a 45-day option to acquire another 1.5 million shares ...That public offering has Tharimmune selling 10 million shares of THAR stock. These shares are being sold for $1 each. Underwriters also have a 45-day option to acquire another 1.5 million shares .... Small cap energy stocks